Preventing Euglycemic Ketoacidosis During Modern Diabetes Therapy

Abstract

Euglycemic diabetic ketoacidosis (EDKA) is an underrecognized and potentially life-threatening complication, particularly associated with the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors in modern diabetes management. Unlike classic diabetic ketoacidosis (DKA), EDKA is characterized by significant metabolic acidosis and ketosis in the setting of normal or near-normal blood glucose levels. This review synthesizes current evidence regarding the epidemiology, underlying pathophysiological mechanisms, risk factors, clinical presentation, diagnostic challenges, and management strategies for EDKA, with a focus on prevention in clinical practice. It further explores recent advances and guideline-based recommendations to equip clinicians with a comprehensive understanding for optimizing patient safety during contemporary diabetes therapy.

Introduction

The landscape of diabetes therapy has evolved rapidly with the advent of novel pharmacological agents, notably SGLT2 inhibitors, which offer cardiovascular and renal benefits. However, these advances bring new safety considerations, including the risk of euglycemic diabetic ketoacidosis (EDKA). EDKA poses unique diagnostic and therapeutic challenges due to its atypical glycemic profile, often leading to delayed recognition and intervention. This article aims to provide an in-depth review of EDKA, emphasizing the importance of early identification and preventive strategies in the era of modern diabetes management.

Epidemiology / Disease Burden

EDKA remains relatively rare compared to classic DKA but is of increasing clinical relevance due to rising use of SGLT2 inhibitors. Large post-marketing surveillance studies and pharmacovigilance databases report an incidence of EDKA ranging from 0.16 to 0.76 events per 1000 patient-years in individuals on SGLT2 inhibitors. While the absolute risk is low, the severity of outcomes and potential for missed diagnosis elevate its clinical importance. Both type 1 and type 2 diabetes patients are at risk, although off-label use of SGLT2 inhibitors in type 1 diabetes appears to increase the incidence. EDKA is also reported in patients with other precipitating factors such as acute illness, surgery, prolonged fasting, and reduced insulin doses.

Pathophysiology

The pathogenesis of EDKA involves relative or absolute insulin deficiency paired with increased glucagon activity, resulting in enhanced lipolysis and free fatty acid oxidation to ketone bodies. SGLT2 inhibitors promote renal glucose excretion, lowering plasma glucose but failing to suppress lipolysis and ketogenesis. This mechanism leads to significant ketosis and acidosis without marked hyperglycemia. Additional contributors include reduced carbohydrate intake, dehydration, and stress-induced counterregulatory hormone release. The unique aspect of EDKA is that normoglycemia or only mild hyperglycemia masks the severity of the underlying metabolic derangement.

Risk Factors

Several clinical factors predispose patients to EDKA during modern diabetes therapy. These include initiation or uptitration of SGLT2 inhibitors, concomitant reduction in insulin doses, acute illnesses (e.g., infections, myocardial infarction), perioperative periods, prolonged fasting or low-carbohydrate diets, excessive alcohol consumption, pregnancy, and conditions causing dehydration or increased insulin requirements. Patients with latent autoimmune diabetes in adults (LADA) or insulin-deficient states are also at heightened risk. Recognizing these risk factors is vital for implementing preventive strategies.

Clinical Features

EDKA presents with non-specific symptoms such as nausea, vomiting, abdominal pain, malaise, polyuria, polydipsia, and altered mental status. Physical findings may include signs of dehydration, tachypnea, and, in severe cases, shock or coma. Importantly, the absence of significant hyperglycemia can mislead clinicians, delaying diagnosis and treatment. Awareness of the clinical context—particularly recent changes in diabetes medications or concurrent stressors—is essential for early suspicion.

Diagnosis

The diagnosis of EDKA requires a high index of suspicion and relies on detecting metabolic acidosis (arterial pH <7.3, serum bicarbonate <18 mmol/L), elevated anion gap, and positive serum or urine ketones, in the presence of blood glucose levels typically <250 mg/dL (13.9 mmol/L). Measurement of beta-hydroxybutyrate is particularly useful. Exclusion of other causes of metabolic acidosis is necessary. The diagnostic challenge lies in considering DKA in patients with normal glucose readings, especially those on SGLT2 inhibitors or with known risk factors.

Treatment & Management

Management of EDKA follows the principles of classic DKA with modifications accounting for euglycemia. Immediate discontinuation of SGLT2 inhibitors is mandatory. Intravenous fluid resuscitation, correction of electrolyte imbalances, and insulin infusion are cornerstone interventions. Glucose supplementation may be required to prevent hypoglycemia during insulin therapy, given the normal baseline glucose. Monitoring for resolution of ketosis and acidosis, as well as careful adjustment of insulin and fluid regimens, is critical. Patient education regarding sick-day rules and early medical contact during illness or surgery is crucial for prevention.

Recent Advances / Emerging Therapies

Recent research emphasizes the development of risk stratification tools and clinical decision aids to guide SGLT2 inhibitor use in high-risk populations. Studies are exploring modified perioperative management protocols, such as temporary discontinuation of SGLT2 inhibitors before elective procedures. Biomarker-based approaches for early detection of ketosis, telemedicine support for patient monitoring, and ongoing clinical trials evaluating adjunctive therapies are advancing the field. Enhanced provider education and pharmacovigilance efforts are also contributing to safer diabetes care.

Guideline Recommendations

Major diabetes societies, including the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD), recommend careful patient selection for SGLT2 inhibitors, routine education about the risk of EDKA, and prompt discontinuation of these agents during acute illness, surgery, or reduced oral intake. Guidelines advocate regular monitoring of ketone levels in at-risk patients and emphasize the importance of sick-day management protocols. Multidisciplinary collaboration among endocrinologists, primary care providers, and perioperative teams is encouraged to optimize safety.

Conclusion

Euglycemic ketoacidosis is an emerging clinical entity in the context of modern diabetes therapy, particularly with SGLT2 inhibitor use. Prevention hinges on awareness of risk factors, patient and provider education, and adherence to evidence-based guidelines. Early recognition and intervention are crucial for reducing morbidity and mortality. Continued research and systematic implementation of preventive strategies will be key to maximizing the benefits of contemporary diabetes treatments while minimizing associated risks.